scholarly journals Why Nigeria Must Strengthen its Local Pharmaceutical Manufacturing Capacity

2021 ◽  
Vol 12 (4) ◽  
pp. 3
Author(s):  
Melody Okereke ◽  
Adebowale Adekunbi ◽  
Yusuf Ghazali
Keyword(s):  
Pharmaceutical Industry ◽  
Raw Materials ◽  
Pharmaceutical Manufacturing ◽  
Active Pharmaceutical Ingredients ◽  
Local Production ◽  
Close Attention ◽  
Developmental Issues ◽  
Pharmaceutical Ingredients ◽  
Pharmaceutical Manufacturers ◽  
Significant Attention

With over 115 registered pharmaceutical manufacturers, Nigeria still depends on other countries for the supply of active pharmaceutical ingredients and excipients. Significant attention has not been paid to the local production of raw materials, pharmaceutical dosage formulations, or processing equipment, which has resulted in a decline in the country's pharmaceutical manufacturing capacity. Owing to the overall importance of the pharmaceutical industry, it is, therefore, essential to pay close attention to developmental issues affecting this sector. In this commentary, we explore why Nigeria must boost its local pharmaceutical manufacturing capacity.

scholarly journals SELF-SUFFICIENCY IN MANUFACTURE OF APIS AND INTERMEDIATES IS A NECESSITY FOR THE INDIAN PHARMACEUTICAL INDUSTRY

INDIAN DRUGS ◽  
2018 ◽  
Vol 55 (04) ◽  
pp. 5-6
Author(s):  
Shreerang Joshi ◽  
Keyword(s):  
Pharmaceutical Industry ◽  
Raw Materials ◽  
Building Blocks ◽  
Dosage Forms ◽  
Considerable Extent ◽  
Active Pharmaceutical Ingredients ◽  
Pharmaceutical Ingredients ◽  
Self Sufficiency ◽  
Dear Reader ◽  
Indian Pharmaceutical Industry

Dear Reader, Active Pharmaceutical Ingredients (APIs) are key raw materials to produce pharmaceutical finished dosage forms like tablets, capsules, syrups, ointments etc. Swift growth in new innovations is prodding the interest for generic active pharmaceutical ingredients manufacturers worldwide with the expanded import of key starting materials (KSMs) and building blocks from the emerging markets. The focus of Indian pharmaceutical industry in last two decades has moved towards finished formulations, ignoring in-house manufacture of APIs to a considerable extent.

scholarly journals Encapsulation of Active Pharmaceutical Ingredients in Lipid Micro/Nanoparticles for Oral Administration by Spray-Cooling

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1186
Author(s):  
Carmen S. Favaro-Trindade ◽  
Fernando E. de Matos Junior ◽  
Paula K. Okuro ◽  
João Dias-Ferreira ◽  
Amanda Cano ◽  
...  
Keyword(s):  
Oral Administration ◽  
Raw Materials ◽  
Low Cost ◽  
Pharmaceutical Formulations ◽  
Spray Cooling ◽  
Active Pharmaceutical Ingredients ◽  
Pharmaceutical Ingredients ◽  
Taste And Odor ◽  
Cooling Technology ◽  
Simple Technology

Nanoencapsulation via spray cooling (also known as spray chilling and spray congealing) has been used with the aim to improve the functionality, solubility, and protection of drugs; as well as to reduce hygroscopicity; to modify taste and odor to enable oral administration; and many times to achieve a controlled release profile. It is a relatively simple technology, it does not require the use of low-cost solvents (mostly associated to toxicological risk), and it can be applied for lipid raw materials as excipients of oral pharmaceutical formulations. The objective of this work was to revise and discuss the advances of spray cooling technology, with a greater emphasis on the development of lipid micro/nanoparticles to the load of active pharmaceutical ingredients for oral administration.

Towards 4th industrial revolution efficient and sustainable continuous flow manufacturing of active pharmaceutical ingredients

2022 ◽  
Author(s):  
Cloudius Sagandira ◽  
Sinazo Nqeketo ◽  
Kanysile Mhlana ◽  
Thembela Sonti ◽  
Paul Watts ◽  
...  
Keyword(s):  
Pharmaceutical Industry ◽  
Continuous Flow ◽  
Industrial Revolution ◽  
Flow Chemistry ◽  
Active Pharmaceutical Ingredients ◽  
New Paradigm ◽  
Pharmaceutical Ingredients ◽  
Continuous Flow Chemistry

Continuous flow chemistry has opened a new paradigm in both the laboratory and pharmaceutical industry. This review details the recently reported literature on continuous multistep telescoped synthesis of active pharmaceutical...

DOMESTIC APIS AND INTERMEDIATES – THE NEED OF THE HOUR

INDIAN DRUGS ◽  
2018 ◽  
Vol 55 (09) ◽  
pp. 5-6
Author(s):  
George Patani ◽  
Keyword(s):  
Pharmaceutical Industry ◽  
Multiple Representations ◽  
Active Pharmaceutical Ingredients ◽  
Current Crisis ◽  
Pharmaceutical Ingredients ◽  
Essential Drugs ◽  
Current Events ◽  
Dear Reader ◽  
The Cost

Dear Reader, As I write this editorial, some of the current events that we are faced with in the pharmaceutical industry in INDIA, bears greatly on my mind. The exponential rise in the cost of a large number of APIs is causing great anguish and stress for formulation manufacturers. The rise in the cost of these APIs or their intermediates sourced from China is attributed as the reason for this increase. As a result, a number of essential drugs are experiencing shortages in various parts of our country. The year 2015 was declared as the year of ACTIVE PHARMACEUTICAL INGREDIENTS (APIs) by the Department of Pharmaceuticals. While we still await the announcement of concessions based on the multiple representations made to the various ministries, the current crisis maybe a god sent opportunity for the domestic API manufacturers to restart manufacturing a number of the APIs that were uneconomical due to price pressures from APIs produced in China

Chemometric approaches to low-content quantification (LCQ) in solid-state mixtures using Raman mapping spectroscopy

2017 ◽  
Vol 9 (44) ◽  
pp. 6293-6301 ◽  
Author(s):  
Boyan Li ◽  
Yannick Casamayou-Boucau ◽  
Amandine Calvet ◽  
Alan G. Ryder
Keyword(s):  
Solid State ◽  
Pharmaceutical Manufacturing ◽  
Active Pharmaceutical Ingredients ◽  
Raman Mapping ◽  
Pharmaceutical Ingredients

The low-content quantification (LCQ) of active pharmaceutical ingredients or impurities in solid mixtures is important in pharmaceutical manufacturing and analysis.

scholarly journals Funding of clinical trials in Brazil for the development of new drugs: who are the sponsors?

2015 ◽  
Vol 2 (4) ◽  
pp. 75 ◽  
Author(s):  
Ricardo Eccard da Silva ◽  
Angélica Amorim Amato ◽  
Maria Rita Carvalho Garbi Novaes
Keyword(s):  
Clinical Trials ◽  
Pharmaceutical Industry ◽  
The Other ◽  
New Drugs ◽  
Essential Medicines ◽  
Neglected Diseases ◽  
Active Pharmaceutical Ingredients ◽  
Pharmaceutical Ingredients ◽  
Funding Sources ◽  
Other Hand

<p class="abstract"><strong>Background:</strong> A low rate of investment in science it is directly impacts the technological independence and capacity in health care costs. Knowledge of funding sources is critical to understand the problem and formulates hypotheses for future studies.</p><p class="abstract"><strong>Methods:</strong> Two databases were used: the System for Control of Clinical Research (SCCR) from the Brazilian Health Surveillance Agency (Anvisa), and the International Clinical Trials Registry Platform (ICTRP).  </p><p class="abstract"><strong>Results:</strong> From 2009 to 2012, 77% of the clinical trials approved by Anvisa were sponsored by transnational pharmaceutical industry. On the other hand, the national pharmaceutical industry sponsored 8% of the trials over the same period. The most frequent sponsor of clinical trials involving drugs registered in the ICTRP from 2011 to 2012 was the transnational pharmaceutical industry (43%). Among the trials with national sponsors, are those involving neglected diseases such as chronic hepatitis C (ICD X B18.2), cutaneous leishmaniasis (ICD X B55.1) and yellow fever (ICD X A95), which were all sponsored by national governmental foundations. None of the active pharmaceutical ingredients studied by the transnational pharmaceutical industry or the transnational biopharmaceutical company were in the national list of essential medicines. On the other hand, 83% and 66.6% of the active pharmaceutical ingredients studied by national private universities and the international governmental agency, respectively, are in the national list of essential medicines.  </p><p class="abstract"><strong>Conclusions:</strong> The national pharmaceutical industry and government still invests little in Research and Development (R&amp;D) activities, when compared with transnational industries. This affects directly its technological and innovation ability.</p>

A REVIEW ON MOUTH DISSOLVING TABLETS

INDIAN DRUGS ◽  
2013 ◽  
Vol 50 (11) ◽  
pp. 5-14
Author(s):  
S. Rathod ◽  
◽  
M. Phansekar ◽  
A. Bhagwan ◽  
G. Surve
Keyword(s):  
Pharmaceutical Industry ◽  
Oral Cavity ◽  
Spray Drying ◽  
Active Pharmaceutical Ingredients ◽  
Pharmaceutical Ingredients ◽  
Moisture Treatment ◽  
Additional Water ◽  
Fast Dissolution ◽  
Increasing Demand

Mouth Dissolving Tablets (MDTs) have received ever-increasing demand during the last decade and the field has become a rapidly growing area of research in the pharmaceutical industry. Upon introduction into the mouth, these tablets dissolve or disintegrate in the mouth in the absence of additional water for easy administration of active pharmaceutical ingredients. The popularity and usefulness of the formulation resulted in development of several MDT technologies. This review describes various formulations and technologies developed to achieve fast dissolution/dispersion of tablets in the oral cavity. In particular, this review describes in detail MDT technologies based on lyophilization, moulding, sublimation and compaction, as well as approaches to enhance the MDT properties, such as spray drying, moisture treatment, sintering, and use of sugar-based disintegrants.

Heterogeneous vanadium catalyzed oxidative cleavage of olefins for sustainable synthesis of carboxylic acids

2021 ◽  
Author(s):  
Rahul Upadhayay ◽  
Rohit Rana ◽  
Aakriti Sood ◽  
Vikash Singh ◽  
Rahul Kumar ◽  
...  
Keyword(s):  
Pharmaceutical Industry ◽  
Carboxylic Acids ◽  
Oxidative Cleavage ◽  
Active Pharmaceutical Ingredients ◽  
Pharmaceutical Ingredients ◽  
A Priority

The development of green and sustainable processes to synthesize active pharmaceutical ingredients and key starting materials is a priority for the pharmaceutical industry. A green and sustainable protocol for the...

15.1 Flow Chemistry in the Pharmaceutical Industry: Part 1

2018 ◽  
Author(s):  
A. G. O’Brien
Keyword(s):  
Pharmaceutical Industry ◽  
Large Scale ◽  
Flow Chemistry ◽  
Active Pharmaceutical Ingredients ◽  
Flow Process ◽  
Pharmaceutical Ingredients ◽  
Multistep Synthesis

Abstract The use of flow chemistry in the single- and multistep synthesis of active pharmaceutical ingredients has been well demonstrated. The pharmaceutical industry is now taking the next steps towards integration of flow chemistry into large-scale commercialized processes, which can effectively supply patient populations. This chapter details advances in this area, and outlines the data and knowledge required to select, develop, scale, and commercialize an efficient flow process.

Sign in / Sign up

Export Citation Format

Share Document